|
Market Closed -
London S.E.
11:20:00 2026-08-18 EDT
|
5-day change | 1st Jan Change | ||
| 323.90 CHF | 0.00% |
|
0.00% | -1.29% |
| 08-13 | Drugmakers curb Swiss reimbursement applications over US pricing concerns | RE |
| 08-11 | Global drugmakers invest billions to boost US presence | RE |
Company Valuation: Roche Holding AG
Data adjusted to current consolidation scope
| Fiscal Period: December | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 | 2028 |
|---|---|---|---|---|---|---|---|---|
| Market Cap 1 | 306,810 | 239,812 | 197,073 | 205,191 | 262,098 | 288,182 | - | - |
| Change | - | -21.84% | -17.82% | 4.12% | 27.73% | 9.95% | - | - |
| Enterprise Value (EV) 1 | 324,977 | 255,396 | 215,772 | 222,528 | 278,258 | 299,049 | 292,202 | 284,185 |
| Change | - | -21.41% | -15.51% | 3.13% | 25.04% | 7.47% | -2.29% | -2.74% |
| P/E | 23.4x | 18.9x | 17.1x | 24.8x | 20.5x | 20.1x | 17.8x | 16.5x |
| PBR | 13.2x | 8.29x | 5.91x | 5.67x | 7.8x | 7.22x | 6.05x | 5.11x |
| PEG | - | -3.69x | -2.48x | -0.9x | 0.4x | 1.7x | 1.4x | 1.97x |
| Capitalization / Revenue | 4.89x | 3.79x | 3.36x | 3.39x | 4.26x | 4.6x | 4.4x | 4.19x |
| EV / Revenue | 5.17x | 4.04x | 3.67x | 3.68x | 4.52x | 4.77x | 4.46x | 4.14x |
| EV / EBITDA | 13.2x | 10.2x | 9.82x | 9.45x | 11.3x | 11.8x | 10.7x | 9.79x |
| EV / EBIT | 14.8x | 11.5x | 11.2x | 10.7x | 12.7x | 13.1x | 12x | 10.9x |
| EV / FCF | 20.7x | 19.6x | 19.1x | 14.5x | 23.6x | 19.5x | 17.9x | 16.1x |
| FCF Yield | 4.83% | 5.11% | 5.23% | 6.89% | 4.24% | 5.13% | 5.59% | 6.21% |
| Dividend per Share 2 | 9.3 | 9.5 | 9.6 | 9.7 | 9.8 | 9.992 | 10.22 | 10.49 |
| Rate of return | 2.45% | 3.27% | 3.93% | 3.8% | 2.99% | 2.77% | 2.83% | 2.91% |
| EPS 2 | 16.2 | 15.37 | 14.31 | 10.31 | 16.04 | 17.95 | 20.23 | 21.92 |
| Distribution rate | 57.4% | 61.8% | 67.1% | 94.1% | 61.1% | 55.7% | 50.5% | 47.9% |
| Net sales 1 | 62,801 | 63,281 | 58,716 | 60,495 | 61,516 | 62,645 | 65,471 | 68,719 |
| EBITDA 1 | 24,692 | 25,015 | 21,976 | 23,538 | 24,608 | 25,289 | 27,246 | 29,015 |
| EBIT 1 | 21,897 | 22,173 | 19,240 | 20,823 | 21,833 | 22,803 | 24,388 | 25,991 |
| Net income 1 | 13,930 | 12,421 | 11,498 | 8,277 | 12,880 | 14,506 | 16,332 | 17,553 |
| Net Debt 1 | 18,167 | 15,584 | 18,699 | 17,337 | 16,160 | 10,867 | 4,020 | -3,998 |
| Reference price 2 | 379.10 | 290.50 | 244.50 | 255.50 | 328.20 | 360.90 | 360.90 | 360.90 |
| Nbr of stocks (in thousands) | 800,952 | 800,579 | 798,652 | 796,789 | 796,317 | 796,766 | - | - |
| Announcement Date | 2/3/22 | 2/2/23 | 2/1/24 | 1/30/25 | 1/29/26 | - | - | - |
1CHF in Million2CHF
Estimates
P/E, Detailed evolution
| P/E (Y) | EV / Sales (Y) | EV / EBITDA (Y) | Dividend Yield (Y) | Capi.($) | ||
|---|---|---|---|---|---|---|
 | 33.85x | 12.21x | 24.91x | 0.58% | 1,055B | |
| 29.18x | - | - | 2.05% | 632B | |
| 31.95x | 7.44x | 15.46x | 2.74% | 442B | |
| 19.84x | 4.71x | 11.68x | 2.81% | 351B | |
| 21.63x | 5.59x | 13.89x | 2.87% | 290B | |
| 20.07x | 4.15x | 11.78x | 2.12% | 243B | |
| 26.53x | 6.9x | 12.24x | 2.4% | 227B | |
| 13.3x | 4.74x | 9.93x | 3.86% | 200B | |
| -42.45x | 6.16x | 24.05x | 2.37% | 172B | |
| Average | 17.10x | 6.49x | 15.49x | 2.42% | 401.39B | |
| Weighted average by Cap. | 24.29x | 8.06x | 17.79x | 1.99% |
Y-o-Y evolution of P/E
Historical PBR trend
Evolution Enterprise Value / Sales
Change in Enterprise Value/EBITDA
Year-on-year evolution of the Yield
- Stock Market
- Stocks
- ROP Stock
- 0QOK Stock
- Valuation Roche Holding AG
Select your edition
All financial news and data tailored to specific country editions
